Lipid nanoparticles (LNPs) electric charge is known to control in vivo distribution and expression of mRNA-LNPs for intravascular (IV) administration. Whereas neutral LNPs predominantly end up targeting the liver,reducing the amount of cationic lipid in mRNA-LNPs creates a negative LNP, due to an excess of anionic mRNA, that targeted the spleen after IV injection, versus positively charged LNPs targeting the lung.A novel family of permanent cationic lipids has been developed to answer the next challenges in the development of RNA therapeutics. The combination of an imidazolium polar head and an accentuated molecularcone-shape through improved lipid tail branching, increases formulation stability and facilitates endosomal release, respectively. Due to these properties, cationic LNP (cLNP) have shown promising results in term ofstability, potency, in vivo distribution and targeting

Novel generation of cationic LNP offer new possibilities in the delivery of RNA therapeutics

Download Poster

Need certificate of analysis ?

In order to download a product protocol or a certificate of analysis, please create an account on Polyplus®Portal .

Create an account to discover our

  • Certificate of Analysis
  • Plasmid Design Platform
  • Product Protocols
  • All exclusive gated content
  • e-Newsletter

Create Account Now

Other sources

Check our FAQs

These FAQs are organized by application to guide you to find the best answer possible.

Product Documents

You have access to all the documents related to the Polyplus Products such as MSDS, NHPS and Posters.

Polyplus-transfection Database

Search for publications in the Transfection Database with Polyplus transfection reagents or for transfection conditions. Over 6000 publications, 1000 cell lines and primary cells available.


This lexicon will help you to understand the different terms related to Polyplus products and services.